{'fraction_non_alphanumeric': 0.030303030303030304, 'fraction_numerical': 0.008658008658008658, 'mean_word_length': 5.871287128712871, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Detection of small abnormal B‐Lymphoblast populations at diagnosis of chronic myelogenous leukemia, BCR‐ABL1+: Incidence, phenotypic features, and clinical implications

According to the 2008 World Health Organization (WHO) Classification of Tumors of the Haematopoietic and Lymphoid Tissues, the finding of B lymphoblasts in the blood or bone marrow of a patient with chronic myelogenous leukemia, BCR‐ABL1+ (CML) should raise a concern for progression of the disease to B‐lymphoblastic blast phase. Data addressing the incidence and phenotypic features of abnormal B lymphoblasts in CML, and whether the detection of B lymphoblasts inexorably heralds blast phase in CML, though, are limited.